Repaglinide

Description

Repaglinide is used to control high blood glucose levels in patients with type II diabetes. Patients are advised to follow a strict diet and exercise regimen along with this medicine for the best possible effect.

Side effects

Major & minor side effects for Repaglinide

  • Anxiety
  • Blurred vision
  • Chills
  • Confusion
  • Nausea
  • Headache
  • Increased hunger
  • Bladder pain
  • Lower back or side pain
  • Bloody or cloudy urine

Uses of Repaglinide

What is it prescribed for?

  • Type II Diabetes Mellitus
Read More
Concerns

Commonly asked questions

  • Onset of action
    The effect of this medicine can be observed within 15 to 60 minutes of administration of the dose.
  • Duration of effect
    The effect of this medicine lasts for an average duration of 4 to 6 hours.
  • Safe with alcohol?
    Consumption of alcohol is not recommended during treatment with this medicine due to the increased risk of severe adverse effects.
  • Is it habit forming?
    No habit forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may prescribe a safer alternative based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to repaglinide or any other inactive ingredients present along with it.

Diabetic ketoacidosis

Repaglinide is not recommended for use in patients with diabetic ketoacidosis due to the increased risk of worsening of the patient's condition.

Type I Diabetes mellitus

Repaglinide is not indicated for use in patients with type 1 diabetes mellitus.

Coadministration of Gemfibrozil

Repaglinide is not recommended for use in patients taking gemfibrozil due to the increased risk of hypoglycemia.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may prescribe a safer alternative based on your clinical condition.
General warnings

Use in children

This medicine is not recommended for use in children since the safety and efficacy of use are not clinically established.

Hypoglycemia

This medicine should be used with extreme caution due to the increased risk of sudden hypoglycemia. Close monitoring of blood glucose levels is recommended during treatment with this medicine. Report any symptoms such as drowsiness, weakness, dizziness, lightheadedness, etc. to the doctor immediately. Appropriate dose adjustments may be required based on the clinical condition.

Missed Dose

Take the missed dose as soon as you remember. However, if you have finished eating, skip the missed dose and continue with the next scheduled dose. Do not take extra medicine to make up for the missed dose.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

N/A

Instructions

Consumption of alcohol is not recommended during treatment with this medicine due to the increased risk of severe adverse effects.
Interaction with Medicine

Clopidogrel

Aspirin

Cyclosporine

Gemfibrozil

Gatifloxacin

Benazepril

Disease interactions

Type 1 diabetes mellitus

Repaglinide is contraindicated in patients with type 1 diabetes mellitus.

Cardiovascular disorders

Repaglinide is not recommended for use in patients with a known history of cardiovascular disorders due to the increased risk of death. Replacement with a suitable alternative should be done based on the clinical condition.

Renal Dysfunction

This medicine should be administered with extreme caution in patients suffering from renal diseases due to the increased risk of worsening of the patient's condition. Appropriate dose adjustments and adjustments in the time interval between two doses should be done based on the clinical condition.

Hepatic impairment

This medicine should be administered with extreme caution in patients suffering from liver diseases due to the increased risk of worsening of the patient's condition. Appropriate dose adjustments and adjustments in the time interval between two doses should be done based on the clinical condition.
Food interactions
Consumption of grapefruit juice is not recommended during treatment with this medicine due to the increased risk of severe adverse effects.
Lab interactions
Information not available.
Take Repaglinide before food. Do not take in larger or smaller amounts that advised/prescribed. Consult the doctor if you experience any undesirable side effects. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

To be taken before food

To be taken as instructed by doctor

May cause sleepiness

How it works
It works by acting on the pancreas to release insulin in the body, which helps in reducing the blood glucose levels.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Meglitinides

Schedule

Schedule H

DailyMed - Repaglinide tablet [Internet]. Dailymed.nlm.nih.gov. 2017 [cited 23 August 2017]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68064989-47ea-4ed5-a20e-43c4ef6ec271

EMC [Internet]. 2017 [cited 23 August 2017]. Available from:

https://www.medicines.org.uk/emc/medicine/18980

Prescribing medicines in pregnancy database [Internet]. Therapeutic Goods Administration (TGA). 2017 [cited 23 August 2017]. Available from:

http://www.tga.gov.au/prescribing-medicines-pregnancy-database

Repaglinide - DrugBank [Internet]. Drugbank.ca. 2017 [cited 23 August 2017]. Available from:

https://www.drugbank.ca/drugs/DB00912

Repaglinide: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2017 [cited 23 August 2017]. Available from:

https://medlineplus.gov/druginfo/meds/a600010.html

Toxnet [Internet]. Toxnet.nlm.nih.gov. 2017 [cited 23 August 2017]. Available from:

https://toxnet.nlm.nih.gov/cgi-bin/sis/search2

How will this medicine affect me?

Consult top doctors online and get an answer now
Chat now
Chat now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now
Book now
Something doesn’t feel right?
Report an error

Information on this page was last updated on 7 Sep 2017

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.